Search

Your search keyword '"van Velthuysen, MLF (M. Loes)"' showing total 13 results
Start Over Author "van Velthuysen, MLF (M. Loes)"
13 results on '"van Velthuysen, MLF (M. Loes)"'

1. Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands

Author

Valstar, MH, Schaapveld, M, Broek, EC, van Velthuysen, MLF (M. Loes), de Ridder, M, Schmidt, MK (Marjanka), van Dijk, BAC, Balm, AJM, Smeele, LE, Valstar, MH, Schaapveld, M, Broek, EC, van Velthuysen, MLF (M. Loes), de Ridder, M, Schmidt, MK (Marjanka), van Dijk, BAC, Balm, AJM, and Smeele, LE

Abstract

Salivary and mammary gland tumors show morphological similarities and share various characteristics, including frequent overexpression of hormone receptors and female preponderance. Although this may suggest a common etiology, it remains unclear whether patients with a salivary gland tumor carry an increased risk of breast cancer (BC). Our purpose was to determine the risk of BC in women diagnosed with salivary gland carcinoma (SGC) or pleomorphic adenoma (SGPA). BC incidence (invasive and in situ) was assessed in two nationwide cohorts: one comprising 1567 women diagnosed with SGC and one with 2083 women with SGPA. BC incidence was compared with general population rates using standardized incidence ratio (SIR). BC risk was assessed according to age at SGC/SGPA diagnosis, follow-up time and (for SGC patients) histological subtype. The mean follow-up was 7.0 years after SGC and 9.9 after SGPA diagnosis. During follow-up, 52 patients with SGC and 74 patients with SGPA developed BC. The median time to BC was 6 years after SGC and 7 after SGPA. The cumulative risk at 10 years of follow-up was 3.1% after SGC and 3.5% after SGPA (95% Confidence Interval (95%CI) 2.1%–4.7% and 2.6%–4.6%, respectively). BC incidence was 1.59 times (95%CI 1.19–2.09) higher in the SGC-cohort than expected based on incidence rates in the general population. SGPA-patients showed a 1.48 times (95%CI 1.16–1.86) higher incidence. Women with SGC or SGPA have a slightly increased risk of BC. The magnitude of risk justifies raising awareness, but is no reason for BC screening.

Published
2021

2. Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours

Author

Blazevic, Anela, Brabander, Tessa, Zandee, Wouter, Hofland, Hans, Franssen, Gaston, van Velthuysen, MLF (M. Loes), Feelders, R.A., de Herder, W.W., Blazevic, Anela, Brabander, Tessa, Zandee, Wouter, Hofland, Hans, Franssen, Gaston, van Velthuysen, MLF (M. Loes), Feelders, R.A., and de Herder, W.W.

Abstract

Around two-thirds of patients with small intestinal neuroendocrine tumours are present with a metastatic mesenteric mass. This mass is known to cause intestinal complications, however, little is known on its development over time in the era of targeted therapy. Therefore, we conducted a retrospective study to assess the growth and response to therapy. We found that the growth of the mesenteric mass was detectable in 13.5% over a median time of 3.4 years and peptide receptor radionuclide therapy resulted in size reduction in only 3.8%. This site-specific static growth behavior is important to note when assessing disease progression and therapeutic options. Background: A metastatic mesenteric mass is a hallmark of small intestinal neuroendocrine tumours (SI-NETs). However, little is known on its development over time. Therefore, we conducted a study to assess the evolution of a SI-NET-associated mesenteric mass over time. Methods: Retrospectively, 530 patients with proven SI-NET were included. The presence and growth of a mesenteric mass was assessed using RECIST 1.1 criteria on every consecutive CT-scan until the end of follow-up or resection. Results: At baseline, a mesenteric mass was present in 64% of the patients, of whom 13.5% showed growth of the mesenteric mass with a median time to growth of 40 months. Male gender was the only independent predictor of growth (OR 2.67). Of the patients without a mesenteric mass at the first evaluation, 2.6% developed a pathological mesenteric mass. Treatment with peptide receptor radionuclide therapy (PRRT; N = 132) resulted in an objective size reduction of the mesenteric mass in 3.8%. Conclusion: The metastatic mesenteric mass in SI-NETs has a static behavior over time. Therefore, site-specific growth behavior should be taken into account when selecting target lesions and assessing disease progression and therapeutic response. PRRT appears not to be effective for size reduction of the mesenteric mass.

Published
2021

4. Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age

Author

Toes - Zoutendijk, Esther, Kooyker, Arthur, Dekker, E, Spaander, Manon, Winden, Annemieke, Ramakers, Christian, Buskermolen, Maaike, van Vuuren, Hanneke, Kuipers, Ernst, van Kemenade, Folkert, van Velthuysen, MLF (M. Loes), Thomeer, Maarten, Ballegooijen, Marjolein, Nagtegaal, ID, de Koning, Harry, Leerdam, M, Lansdorp - Vogelaar, Iris, Toes - Zoutendijk, Esther, Kooyker, Arthur, Dekker, E, Spaander, Manon, Winden, Annemieke, Ramakers, Christian, Buskermolen, Maaike, van Vuuren, Hanneke, Kuipers, Ernst, van Kemenade, Folkert, van Velthuysen, MLF (M. Loes), Thomeer, Maarten, Ballegooijen, Marjolein, Nagtegaal, ID, de Koning, Harry, Leerdam, M, and Lansdorp - Vogelaar, Iris

Published
2020

5. Granular dot-like staining with MLH1 immunohistochemistry is a clone-dependent artefact

Author

Dasgupta, Shatavisha, Graham, Patricia, Groenendijk, Floris, Stam, O, Biermann, Katharina, Doukas, Michail, Dubbink, Erik jan, van Velthuysen, MLF (M. Loes), Dinjens, Winand, Bockstal, Mieke, Dasgupta, Shatavisha, Graham, Patricia, Groenendijk, Floris, Stam, O, Biermann, Katharina, Doukas, Michail, Dubbink, Erik jan, van Velthuysen, MLF (M. Loes), Dinjens, Winand, and Bockstal, Mieke

Published
2020

6. Interobserver, intraobserver, and interlaboratory variability in reporting pT4a colon cancer

Author

Klaver, CEL, Bulkmans, N, Drillenburg, P, Grabsch, HI, van Grieken, NCT, Karrenbeld, A, Koens, L, van Lijnschoten, I, Meijer, J, Nagtegaal, ID, Sagaert, X, Seldenrijk, K, van Velthuysen, MLF (M. Loes), Bruggink, AH, Tanis, PJ, Snaebjornsson, P, Klaver, CEL, Bulkmans, N, Drillenburg, P, Grabsch, HI, van Grieken, NCT, Karrenbeld, A, Koens, L, van Lijnschoten, I, Meijer, J, Nagtegaal, ID, Sagaert, X, Seldenrijk, K, van Velthuysen, MLF (M. Loes), Bruggink, AH, Tanis, PJ, and Snaebjornsson, P

Published
2020

7. Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries

Author

Vigliar, E, Cepurnaite, R, Alcaraz-Mateos, E, Ali, SZ, Baloch, ZW, Bellevicine, C, Bongiovanni, M, Botsun, P, Bruzzese, D, Bubendorf, L, Büttner, R, Canberk, S, Capitanio, A, Casadio, C, Cazacu, E, Cochand-Priollet, B, D’Amuri, A, Eloy, C, Engels, M, Fadda, G, Fontanini, G, Fulciniti, F, Hofman, P, Iaccarino, A, Ieni, A, Jiang, XS, Kakudo, K, Kern, I, Kholova, I, Liu, Chang, Lobo, A, Lozano, MD, Malapelle, U, Maleki, Z, Michelow, P, Musayev, J, Özgün, G, Oznur, M, Peiró Marqués, FM, Pisapia, P, Poller, D, Pyzlak, M, Robinson, B, Rossi, ED, Roy-Chowdhuri, S, Saieg, M, Savic Prince, S, Schmitt, FC, Javier Seguí Iváñez, F, Štoos-Vei?, T, Sulaieva, O, Sweeney, BJ, Tuccari, G, van Velthuysen, MLF (M. Loes), VanderLaan, PA, Vielh, P, Viola, P, Voorham, R, Weynand, B, Zeppa, P, Faquin, WC, Pitman, MB, Troncone, G, Vigliar, E, Cepurnaite, R, Alcaraz-Mateos, E, Ali, SZ, Baloch, ZW, Bellevicine, C, Bongiovanni, M, Botsun, P, Bruzzese, D, Bubendorf, L, Büttner, R, Canberk, S, Capitanio, A, Casadio, C, Cazacu, E, Cochand-Priollet, B, D’Amuri, A, Eloy, C, Engels, M, Fadda, G, Fontanini, G, Fulciniti, F, Hofman, P, Iaccarino, A, Ieni, A, Jiang, XS, Kakudo, K, Kern, I, Kholova, I, Liu, Chang, Lobo, A, Lozano, MD, Malapelle, U, Maleki, Z, Michelow, P, Musayev, J, Özgün, G, Oznur, M, Peiró Marqués, FM, Pisapia, P, Poller, D, Pyzlak, M, Robinson, B, Rossi, ED, Roy-Chowdhuri, S, Saieg, M, Savic Prince, S, Schmitt, FC, Javier Seguí Iváñez, F, Štoos-Vei?, T, Sulaieva, O, Sweeney, BJ, Tuccari, G, van Velthuysen, MLF (M. Loes), VanderLaan, PA, Vielh, P, Viola, P, Voorham, R, Weynand, B, Zeppa, P, Faquin, WC, Pitman, MB, and Troncone, G

Published
2020

9. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

Author

Beukhof, CM (Carolien), Brabander, Tessa, Nederveen, Francien, van Velthuysen, MLF (M. Loes), de Rijke, Yolanda, Hofland, Leo, Franssen, Gaston, Froberg, A, Kam, BLR, Visser, Edward, de Herder, W.W., Peeters, Robin, Beukhof, CM (Carolien), Brabander, Tessa, Nederveen, Francien, van Velthuysen, MLF (M. Loes), de Rijke, Yolanda, Hofland, Leo, Franssen, Gaston, Froberg, A, Kam, BLR, Visser, Edward, de Herder, W.W., and Peeters, Robin

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results